1921
Volume 93, Issue 3
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

This was a double-blind, randomized, controlled, phase II clinical trial, two dose study of re-derived, live-attenuated, tetravalent dengue virus (TDEN) vaccine (two formulations) or placebo in subjects 1–50 years of age. Among the 636 subjects enrolled, 331 (52%) were primed, that is, baseline seropositive to at least one dengue virus (DENV) type. Baseline seropositivity prevalence increased with age (10% [< 2 years], 26% [2–4 years], 60% [5–20 years], and 93% [21–50 years]). Safety profiles of TDEN vaccines were similar to placebo regardless of priming status. No vaccine-related serious adverse events (SAEs) were reported. Among unprimed subjects, immunogenicity (geometric mean antibody titers [GMT] and seropositivity rates) for each DENV increased substantially in both TDEN vaccine groups with at least 74.6% seropositive for four DENV types. The TDEN vaccine candidate showed an acceptable safety and immunogenicity profile in children and adults ranging from 1 to 50 years of age, regardless of priming status. ClinicalTrials.gov: NCT00468858.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.14-0625
2015-09-02
2017-09-23
Loading full text...

Full text loading...

/deliver/fulltext/14761645/93/3/441.html?itemId=/content/journals/10.4269/ajtmh.14-0625&mimeType=html&fmt=ahah

References

  1. Centers for Disease Control and Prevention (CDC), 2012. Dengue World Health Organization (WHO) Technical Report Series, No. 932, 2006 Annex 1. Guidelines for the Production and Quality Control of Candidate Tetravalent Dengue Virus Vaccines (Live). Available at: http://www.cdc.gov/dengue/. Accessed October 8, 2013.
  2. World Health Organization (WHO), 2012. Global Strategy for Dengue Prevention and Control, 2012–2020. WHO Report. Geneva, Switzerland: WHO/HTM/NTD/VEM/2012.5.
  3. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GR, Simmons CP, Scott TW, Farrar JJ, Hay SI, , 2013. The global distribution and burden of dengue. Nature 496: 504507.[Crossref]
  4. Knope K, National Arbovirus and Malaria Advisory Committee Giele C, ; , , 2013. Increasing notifications of dengue in Australia related to overseas travel, 1991 to 2012. Commun Dis Intell Q Rep 37: e55e59.
  5. Badurdeen S, Valladares DB, Farrar J, Gozzer E, Kroeger A, Kuswara N, Ranzinger SR, Tinh HT, Leite P, Mahendradhata Y, Skewes R, Verrall A, European Union, World Health Organization (WHO-TDR) supported IDAMS study group; , 2013. Sharing experiences: towards an evidence based model of dengue surveillance and outbreak response in Latin America and Asia. BMC Public Health 13: 607.[Crossref]
  6. World Health Organization (WHO), 2013. Impact of Dengue. Available at: http://www.who.int/csr/disease/dengue/impact/en/. Accessed October 9, 2013.
  7. Centers for Disease Control and Prevention (CDC), 2011. The Dengue Update: 2010: Largest Dengue Outbreak in Puerto Rico history. Vol. 3, No. 1. Available at: http://www.cdc.gov/Dengue/dengue_upd/index.html#outbreak. Accessed March 21, 2014.
  8. Innis BL, Eckels KH, , 2003. Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command. Am J Trop Med Hyg 69: 14.
  9. Edelman R, Wasserman S, Bodison S, Putnak R, Eckels K, Tang D, Kanesa-Thasan N, Vaughn D, Innis B, Sun W, , 2003. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg 69 (Suppl): 4860.
  10. Simasathien S, Thomas SK, Watanaveeradej V, Nisalak A, Barberousse C, Innis B, Sunn W, Putnak R, Eckels K, Hutagalung Y, Gibbons R, Zhang C, De La Barrera R, Jarman R, Chawachalasai W, Mammen M, , 2008. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naïve children. Am J Trop Med Hyg 78: 426433.
  11. Watanaveeradej V, Simasathien S, Nisalak A, Endy TP, Jarman RG, Innis BL, Thomas SJ, Gibbons RV, Hengprasert S, Samakoses R, Kerdpanich A, Vaughn DW, Putnak JR, Eckels KH, De La Barrera R, Mammen MP, Jr, 2011. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus-naive infants. Am J Trop Med Hyg 85: 341351.[Crossref]
  12. Thomas SJ, Eckels KH, Carletti I, De La Barrera R, Dessy F, Fernandez S, Putnak R, Toussaint JF, Sun W, Bauer K, Gibbons RV, Innis BL, , 2013. A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults. Am J Trop Med Hyg 88: 7388.[Crossref]
  13. Watanaveeradej V, Gibbons RV, Simasathien S, Nisalak A, Jarman RG, Kerdpanich A, Tournay E, De La Barrerra R, Dessy F, Toussaint JF, Eckels KH, Thomas SJ, Innis BL, , 2014. Safety and immunogenicity of a re-derived, live-attenuated dengue virus vaccine in healthy adults living in Thailand: a randomized trial. Am J Trop Med Hyg 91: 119128.[Crossref]
  14. Schulz KF, Altman DG, Moher D, Consort Group; , 2010. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ 340: c332.[Crossref]
  15. International Committee on Harmonization, 2014. Medical Dictionary for Regulatory Activities. Available at: http://www.medra.org/. Accessed August 1, 2014.
  16. Lee IK, Lee WH, Liu JW, Yang KD, , 2010. Acute myocarditis in dengue hemorrhagic fever: a case report and review of cardiac complications in dengue-affected patients. Int J Infect Dis 14: e919e922.[Crossref]
  17. Sadon N, Delers A, Jarman RG, Klungthong C, Nisalak A, Gibbons RV, Vassilev V, , 2008. A new quantitative RT-PCR method for sensitive detection of dengue virus in serum samples. J Virol Methods 153: 16.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.14-0625
Loading
/content/journals/10.4269/ajtmh.14-0625
Loading

Data & Media loading...

Supplementary Data

Supplementary PDF

  • Received : 07 Oct 2014
  • Accepted : 24 Feb 2015

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error